Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

ashington, l	D.C.	20549	
--------------	------	-------	--

STATEMENT	OF	CHANGES	IN BENE	EFICIAL	OWNERS	HIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Williams Timothy				2. Issuer Name <b>and</b> Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]								5. (C	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner			wner			
(Last) 2200 PE	(Fi	rst) (M	Middle	*)	3. Date of Earliest Transaction (Month/Day/Year) 03/04/2024								X	belov	er (give title v) VP & Gen	eral	Other (something the below)  Counsel	specify	
SUITE 300E					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WASHIN	NGTON DO	C 2	0037			X Form filed by One Reporting Person  Form filed by More than One Reporting Person													
(City)	(St	ate) (2	Zip)		Rule 10b5-1(c) Transaction Indication							on							
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/N			rear)	Execution Date		·	Transaction Disposed Of (		Acquired (A) or (D) (Instr. 3, 4 and 5)		5)	Beneficially Owned Following		Forr (D)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 03/04/20					24	24			<b>S</b> <sup>(1)</sup>		8,147	D	\$4.408	086 <sup>(2)</sup> 20		5,766		D	
Common Stock 03/05/202					24				<b>S</b> <sup>(1)</sup>		8,941	D	\$4.182	5(3)	19	06,825		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if an	Deemed ution Date, y yth/Day/Year)	Date, Transaction of Code (Instr. Deriv			rities ired r osed ) : 3, 4	Expiration Date (Month/Day/Year) Amount of Securitive Underlyin Derivative Security (3 and 4)			Int of rities rlying ative rity (Instr. 4)  Amount or Number	unt		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(A) (D)		cisable	Expiration Date	Title	of Shares						

## **Explanation of Responses:**

- 1. Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.405 to \$4.412, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.175 to \$4.1901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

/s/ Timothy Williams 03/06/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.